Singapore-based firms KhattarWong and WongPartnership, together with international players Conyers Dill and Pearman and Paul Weiss have had a hand in China Pharma's proposed acquisition of the SGX-listed Sihuan Pharmaceutical Holdings Group. PRC firm Commerce & Finance was also involved in the deal.

Sihuan is engaged in the research, production and sale of pharmaceutical drugs, with a focus on cardio cerebral vascular drugs. China Pharma Holdings, which is a subsidiary of Morgan Stanley Private Equity Asia III Holdings (Cayman), launched a voluntary conditional cash offer to acquire the entire issued share capital of Sihuan.

The offer price of S$0.975 per share is based on a valuation of the company at S$458m. Sichuan's controlling shareholders, who currently own over 75% of the shares in issue, have entered into arrangements to tender all their shares to China Pharma.

A Paul Weiss team led by partner Jack Lange was retained by China Pharma for advice. For Singapore, Bermudan and PRC legal issues the company turned to WongPartnership, Conyers Dill & Pearman and Commerce & Finance, respectively. KhattarWong were brought on board as counsel for Sihuan.